Actively Recruiting
Imjudo & Imfinzi PMS
Led by AstraZeneca · Updated on 2025-11-21
246
Participants Needed
6
Research Sites
202 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Based on the re-review of new drugs article, Korean pharmaceutical act, the objectives of this study are to assess safety and effectiveness of the study drugs(Imjudo \& Imfinzi) in a real world setting in patients who treated according to the approved indications in Korea.
CONDITIONS
Official Title
Imjudo & Imfinzi PMS
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients eligible for the study drugs according to the approved label in Korea
- Provision of signed and dated written informed consent by the patient or legally acceptable representative
You will not qualify if you...
- Patients receiving study drugs for indications not approved in South Korea
- Current participation in any interventional clinical trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
Research Site
Busan, South Korea
Actively Recruiting
2
Research Site
Goyang, South Korea
Actively Recruiting
3
Research Site
Seongnam, South Korea
Actively Recruiting
4
Research Site
Seoul, South Korea
Actively Recruiting
5
Research Site
Seoul, South Korea
Not Yet Recruiting
6
Research Site
Suwon, South Korea
Actively Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here